28.42
Schlusskurs vom Vortag:
$1.76
Offen:
$28.55
24-Stunden-Volumen:
1,412
Relative Volume:
167.01
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-129.20
EPS:
-0.22
Netto-Cashflow:
-
1W Leistung:
+1,515%
1M Leistung:
+1,515%
6M Leistung:
+1,515%
1J Leistung:
+1,515%
Second Sight Medical Products, Stock (EYES) Company Profile
Firmenname
Second Sight Medical Products,
Sektor
Branche
Telefon
818-833-5000
Adresse
12744 San Fernando Road, Suite 400, Sylmar
Compare EYES vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
EYES
Second Sight Medical Products,
|
28.42 | 0 | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
102.61 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
92.13 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
275.12 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
43.34 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
88.26 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Second Sight Medical Products, Stock (EYES) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2015-07-06 | Eingeleitet | H.C. Wainwright | Buy |
Second Sight Medical Products, Aktie (EYES) Neueste Nachrichten
Second Sight Medical Products Inc (VANIW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Second Sight Medical Products Inc (VANIW) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Second Sight Medical Products Inc. Warrants (EYESW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Second Sight Medical Products Inc. (EYES) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc (VANIW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Second Sight Medical Products Inc (VANIW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
EU Clears PRIMA Retinal Chip for Commercial Sale After AMD Patient Reads 300-Page Novel - The Eastern Herald
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream - GlobeNewswire Inc.
ClearOne skyrockets from neurotech pivot, merger with Cortigent - Mugglehead Investment Magazine
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - markets.businessinsider.com
Vivani Medical allows Novo Nordisk to evaluate NPM-139 - scanx.trade
ClearOne Merging With Cortigent - Pulse 2.0
Vivani to sell neurotech subsidiary Cortigent to ClearOne - MassDevice
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical - Business Wire
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - GlobeNewswire
Vivani Medical appoints August Moretti to board as Dr. Dean Baker retires - scanx.trade
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention - markets.businessinsider.com
European Union Retinal Implant Electrode ArraysMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
World Auditory Brainstem ImplantsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Visual Prosthesis Market Size, Share, Growth, Forecast, 2034 - Straits Research
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026 - markets.businessinsider.com
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Medical Bionic Implant and Artificial Organs Price in the European UnionMarket Insights - IndexBox
Stock List: Research Stocks from Around the World - GuruFocus
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Single semaglutide implant showed >20% weight loss for a year - Stock Titan
Promising Six-Year Early Feasibility Study Results Released for the Orion System - Medical Product Outsourcing
Electroceuticals Market Size, Share & Growth Report, 2034 - Market Data Forecast
'Bionic Eye' Helps Man See After Decade of Impaired VisionABC News - ABC News - Breaking News, Latest News and Videos
Don’t Let Elon Musk Implant a Device in Your Skull - Home ❧ Current Affairs
Vivani Subsidiary Cortigent Presents Promising 6-Year Early - GlobeNewswire
Vivani Subsidiary Cortigent to Present Orion System’s - GlobeNewswire
Artificial Eye Market Size, Share, Growth | CAGR of 7.8% - Market.us
Study Links Rod Cell Evolution to Dinosaur Extinction Event - 동아사이언스
Robert Greenberg Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Science Corp.'s Prima implant enables blind patients to read - bioworld.com
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off - GlobeNewswire
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders - GlobeNewswire
Ocular Implants Market Size, Demand & Revenue Statistics by 2033 - Straits Research
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - GlobeNewswire
EYES Stock Price, News & Analysis - Stock Titan
Vivani to spin off neurostimulation business - MedTech Dive
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business - Business Wire
Sight Care – Study Findings, Reviews, Ingredients and Where to Buy It - GlobeNewswire
Cortigent, Inc IPOs Tomorrow, Here's What You Need To Know - Sahm
Second Sight Medical’s Argus II Recognized by Popular Science Magazine - Medical Product Outsourcing
Bionic Eye Market to Reach US$ 524 Million by 2032 - Market.us Media
Treatment and technology: The future of retina care - Ophthalmology Times Europe
Finanzdaten der Second Sight Medical Products, -Aktie (EYES)
Es liegen keine Finanzdaten für Second Sight Medical Products, (EYES) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kapitalisierung:
|
Volumen (24h):